At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol C1: Crizotinib in Patients With Tumors With MET Amplification
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 2 other interventions for Advanced Lymphoma and 4 related conditions. Active but no longer recruiting, targeting 44 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial tests how well crizotinib works in treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that does not respond to treatment (refractory) and who have MET gene amplification. Crizotinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow.
Study Details
Timeline
Interventions
Undergo biopsy
Undergo collection of blood samples
Given PO
Undergo radiologic evaluation